10th International Conference on Tularemia

第十届土拉菌病国际会议

• 批准号: 10722927
• 负责人: Karl E Klose
• 金额: $ 1.82万
• 依托单位: UNIVERSITY OF TEXAS SAN ANTONIO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10722927
• 关键词: 10th; International; Conference; Tularemia

SUMMARY/ABSTRACT This proposal seeks support for the 10th International Conference on Tularemia, which will be held from September 25 – 28, 2023, in Grenoble, France. Tularemia is a rapidly progressive and potentially fatal zoonosis of humans caused by the intracellular bacterial pathogen, Francisella tularensis. Because of its low infectious dose and lethality when inhaled, F. tularensis was developed as a bioweapon, and remains a potential bioterrorist agent. Research and understanding of tularemia pathogenesis, diagnosis, treatment, and prevention have been significantly advanced by the International Conferences on Tularemia. Attendance and impact of this meeting has grown steadily in subsequent years. This conference is a unique venue that brings together scientists and interested parties from the U.S., Canada, Scandinavia, Europe, the Middle East, and Japan. CBER/FDA has an ongoing commitment to facilitating development of medical countermeasures for bioterrorism and emerging infectious diseases. Advancing development of medical countermeasures is an explicit goal of this meeting. Senior scientists, clinicians, and trainees at all levels attend; attendees with knowledge and interests outside the Francisella community also bring perspective and instructive comparisons. The conference is designed to provide an environment that fosters collaboration and a free exchange of ideas. Highlights from past meetings include announcing the discoveries of the Francisella pathogenicity island (FPI); the Type VI secretion system encoded by the FPI; development of new animal models; detailed genomic and proteomic characterizations that inform epidemiology of disease and development of new therapeutic options; and identification of immune evasion strategies of the bacterium that advance vaccine development. The 2023 conference will include a keynote address as well as six plenary sessions, poster previews (flash talks) and three poster sessions, and additional opportunities for networking during shared meals and social activities. The six plenary sessions will highlight the latest advances in diagnosis and treatment of tularemia, vaccine development, host responses to infection, epidemiology and bacterial ecology, bacterial physiology and gene regulation, and pathogenesis and cell biology. Each plenary session will be chaired by scientists who are recognized leaders in the field. Over 85% of speakers will be selected based on the merit of submitted abstracts. To achieve these goals, we seek support for meeting logistics that will allow dissemination of research findings as well as professional development of attendees. Specifically, we request support for rental of presentation equipment (audiovisual services and poster boards), conference management and web site development, and travel support for attendees with financial and educational needs.

摘要/摘要 该提案寻求第十届土拉菌病国际会议的支持，该会议将于 2023 年 9 月 25 日至 28 日，法国格勒诺布尔，兔热病是一种进展迅速且可能致命的疾病。 由细胞内细菌病原体土拉弗朗西斯菌引起的人类人畜共患病，因为其含量低。 由于吸入时的感染剂量和致死率，土拉弗朗西斯菌被开发为一种生物武器，并且仍然是一种生物武器 潜在的生物恐怖分子对兔热病发病机制、诊断、治疗和认识的研究和了解。 兔热病国际会议的出席和会议极大地促进了预防工作。 这次会议的影响力在随后几年中稳步增长。 来自美国、加拿大、斯堪的纳维亚半岛、欧洲、中东和非洲的科学家和感兴趣的各方聚集在一起 日本 CBER/FDA 持续致力于促进医疗对策的制定。 生物恐怖主义和新出现的传染病是推动医疗对策的发展。 这次会议的明确目标。 弗朗西斯拉社区之外的知识和兴趣也带来了观点和指导 该会议旨在提供一个促进合作和自由的环境。 过去会议的亮点包括宣布弗朗西斯拉的发现。 致病性岛（FPI）；由FPI编码的VI型分泌系统；新动物的开发； 模型；详细的基因组和蛋白质组特征，为疾病的流行病学提供信息； 开发新的治疗方案；以及鉴定细菌的免疫逃避策略 2023 年会议将包括一次主题演讲和六次全体会议。 会议、海报预览（快闪演讲）和三场海报会议以及其他交流机会 在共享餐食和社交活动期间，六次全体会议将重点介绍该领域的最新进展。 兔热病的诊断和治疗、疫苗开发、宿主对感染的反应、流行病学和 细菌生态学、细菌生理学和基因调控、发病机制和细胞生物学。 会议将由该领域公认的领导者科学家主持，超过 85% 的发言人将出席。 根据提交摘要的优点进行选择 为了实现这些目标，我们寻求会议支持。 后勤工作将有助于传播研究成果以及与会者的专业发展。 具体来说，我们请求支持租赁演示设备（视听服务和海报板）， 会议管理和网站开发，以及为有经济和经济能力的与会者提供差旅支持 教育需求。